title: Discovery of hepatitis C virus NS5A inhibitors as a new class of anti-HCV therapy.
abstract: Chronic hepatitis C virus (HCV) infection is responsible for development of liver cirrhosis and hepatocellular carcinoma. In addition to PEGylated interferon-α, ribavirin, and HCV NS3 protease inhibitors, recently identified HCV NS5A inhibitors such as BMS-790052 showed a great promise in clinical trials as another new class of direct-acting anti-HCV therapeutics with a distinct mechanism of action. This clinical proof-of-concept study with NS5A inhibitors demonstrated that small molecules targeting a viral protein without any known enzymatic activity can also have profound antiviral effects. In conclusion, NS5A inhibitors will serve as a valuable component of future therapy for HCV patients.
authors: College of Pharmacy, Dongguk University, Goyang 410-820, Korea. choongholee@dongguk.edu
authors: Choongho
authors: C
authors: Lee
mesh_terms: D000998:Antiviral Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D002219:Carbamates; D002986:Clinical Trials as Topic; D055808:Drug Discovery; D016679:Genome, Viral; D016174:Hepacivirus / Q000187:drug effects* / Q000235:genetics / Q000502:physiology; D006526:Hepatitis C / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D007093:Imidazoles / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D011759:Pyrrolidines; D016896:Treatment Outcome; D014633:Valine / Q000031:analogs & derivatives; D017361:Viral Nonstructural Proteins / Q000037:antagonists & inhibitors* / Q000235:genetics; D014779:Virus Replication / Q000187:drug effects / Q000235:genetics; D012324:RNA-Dependent RNA Polymerase
chemical_list: D000998:Antiviral Agents; D002219:Carbamates; D007093:Imidazoles; D011759:Pyrrolidines; D014633:Valine; D017361:Viral Nonstructural Proteins; C087036:NS-5 protein, hepatitis C virus; D012324:RNA-Dependent RNA Polymerase; C549273:daclatasvir